Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Apr 21, 2020; 26(15): 1805-1819
Published online Apr 21, 2020. doi: 10.3748/wjg.v26.i15.1805
Figure 1
Figure 1 Flow chart for patient eligibility. HCC: Hepatocellular carcinoma; ECOG: Eastern Cooperative Oncology Group.
Figure 2
Figure 2 Kaplan–Meier curves for survival analysis and comparisons. A: Survival analysis of the whole cohort; B: Comparisons among patients with different Child-Pugh class; C: Comparisons among patients with different albumin-bilirubin grade; D: Comparisons among patients with different alpha-fetoprotein level. ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein.
Figure 3
Figure 3 Time-dependent receiver operating characteristic analysis for the proposed prognostic models and six-and-twelve criteria. AUROC: Area under receiver operating characteristic. 6&12: Six-and-twelve.
Figure 4
Figure 4 Subgroup analysis for evaluating the prognostic values of six-and-twelve criteria. HR: Hazard ratio; CI: Confidence interval; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus. 6&12: Six-and-twelve.
Figure 5
Figure 5 Six-and-twelve criteria tools for clinical use in advanced hepatocellular carcinoma patients with Eastern Cooperative Oncology Group performance status score 1 alone. A: Survival prediction for six-and-twelve (6&12) criteria using contour plot of 3-year survival probability; B: Nomogram based on the cut-off value of 6&12 criteria; C: Patient stratification based on the cut-off value of 6&12 criteria.